<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04452136</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00020072</org_study_id>
    <secondary_id>STUDY00020073</secondary_id>
    <nct_id>NCT04452136</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer</brief_title>
  <official_title>68Ga PSMA-11 in Patients With Intermediate to High-risk Prostate Cancer Before Prostatectomy or With Biochemical Recurrence of Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jeanne Link</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OHSU Center of Radiochemistry Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <brief_summary>
    <textblock>
      This study provides expanded access to radiotracer Gallium 68 (68Ga)-prostate-specific&#xD;
      membrane antigen (PSMA)-HBED-CC (68Ga-PSMA-11) with Positron Emission Tomography (PET)&#xD;
      imaging for participants with intermediate and high risk prostate cancer before prostatectomy&#xD;
      or for suspected biochemical recurrence of their prostate cancer. Compared to conventional&#xD;
      imaging, 68Ga PSMA-HBED-CC might improve the ability to localize the sites of recurrent or&#xD;
      metastatic disease, which helps with surgical and other treatment planning.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      Provide participants with prostate cancer access to 68Ga PSMA-HBED-CC to localize the site of&#xD;
      potential metastatic or recurrent disease.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Eligible participants will be intravenously administered 68Ga PSMA-HBED-CC at a dose of 3-7&#xD;
      mCi (111 - 259 MBq), target 5 mCi. The estimated uptake time of the study agent is 75 minutes&#xD;
      ± 25 minutes. The targeted uptake time is 60 minutes, with an acceptable range of 50-100&#xD;
      minutes. Following the PET scan with the study agent, participants will undergo either&#xD;
      surgical management or treatment for metastatic disease in accordance with institutional&#xD;
      standards.&#xD;
&#xD;
      Patients will be observed for 2 hours after injection of the radiotracer, and will be&#xD;
      followed-up 1-3 days post injection with a phone call.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Prostatic Neoplasms</condition>
  <condition>Prostatic Diseases</condition>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Cancer Metastatic</condition>
  <condition>Prostate Cancer Recurrent</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68GA PSMA-HBED-CC</intervention_name>
    <description>Given IV</description>
    <other_name>68Ga-PSMA-11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PLANNED PROSTATECTOMY&#xD;
&#xD;
          -  Biopsy-proven prostate adenocarcinoma&#xD;
&#xD;
          -  Intermediate to high-risk disease, defined as one of the following factors: PSA &gt; 10,&#xD;
             T2b or greater, or a Gleason score of 7 or greater.&#xD;
&#xD;
          -  Planned prostatectomy with lymph node dissection&#xD;
&#xD;
          -  Must be treatment naïve (not have received neoadjuvant chemotherapy, radiation&#xD;
             therapy, hormonal therapy, androgen deprivation therapy, or focal ablation techniques&#xD;
             (e.g., HiFu)&#xD;
&#xD;
        BIOCHEMICAL RECURRENCE&#xD;
&#xD;
          -  Pathologically proven prostate adenocarcinoma. Rising PSA after definitive therapy&#xD;
             with prostatectomy or radiation therapy (external beam or brachytherapy).&#xD;
&#xD;
          -  If post-radical prostatectomy, PSA &gt; 0.2 ng/mL measured &gt; 6 weeks post-operatively and&#xD;
             confirmatory persistent PSA greater than 0.2 ng/mL (AUA recommendation for biochemical&#xD;
             recurrence).&#xD;
&#xD;
          -  If post-radiation therapy, PSA that is equal to or greater than a 2 mg/mL rise above&#xD;
             PSA nadir (ASTRO recommendation for biochemical recurrence).&#xD;
&#xD;
          -  No other malignancy within the past 2 years (skin basal cell or cutaneous superficial&#xD;
             squamous cell carcinoma or superficial bladder cancer are exempt from this criterion).&#xD;
&#xD;
        ALL&#xD;
&#xD;
          -  Karnofsky performance status (KPS) &gt;= 50 (ECOG/WHO 0, 1, or 2)&#xD;
&#xD;
          -  Not receiving any other investigational agents (i.e., unlabeled drugs or drugs under&#xD;
             an IND for initial efficacy investigations&#xD;
&#xD;
          -  Ability to understand and the willingness to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Stevens-Johnson syndrome&#xD;
&#xD;
          -  Known Paget's disease&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Nadine Mallak, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Libby Mirande</last_name>
    <phone>503-494-4740</phone>
    <email>Radresearch@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Libby Mirande</last_name>
      <phone>503-494-4740</phone>
      <email>Radresearch@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Nadine Mallak, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jeanne Link</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

